我院2009～2013年口服降糖药用药分析

目的分析我院2009～2013年近5年来降糖药用药情况，为临床合理用药提供参考。方法通过医院信息管理系统，对2009～2013年我院口服降糖药的销售金额、用药频度（DDDs）、日均费用（DDDc）等进行回顾性分析。结果我院近5年来口服降糖药销售金额排序前2位的是磺酰脲类、胰岛素增敏药；罗格列酮的销售金额始终位居第1位；DDDs值排名位居第1位的是二甲双胍，而DDC排名最低；其中瑞格列奈的用药金额排序和DDDs排序同步性较好。结论我院的口服降糖药使用基本合理，新药用量呈上升趋势，质优价廉的降糖药在临床应用中占优势。

Application analysis of oral hypoglycemic agents of our hospital from 2009 to 2013

Objective To investigate and analyze the application of oral hypoglycemic agents from 2009 to 2013 in our hospital, and provide guidance for rational clinical medication. Methods Depending on the original data from ＂the management system of the drug stock＂, the data of oral hypoglycemic agents were analyzed retrospectively in respect of the consumption sum, DDDs and drug daily cost （DDC） etc. Results. Sulfonylureas and insulin sensitizer ranked the top two places in respect of the consumption sum in our hospital during 2009-2013. Among the insulin sensitizer, rosiglitazone sales amount dominated the first place on the list of consumption sum. Metformin ranked at the front in respect of DDDs and its DDC is the lowest among of them during the five years. The consumption sum of repaglinide has grown in step with DDDs. Conclusion The utilization of oral hypoglycemic agents in our hospital was rational on the whole. The consumption quantity of new drugs showed an upward trend; the kinds of good quality and low price assumed a dominant place in clinical application.